1Department of Neurosurgery, University of Virginia Health System, Charlottesville, Virginia.
8Department of Neurosurgery, University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania; and.
J Neurosurg. 2018 Sep;129(3):648-657. doi: 10.3171/2017.5.JNS163069. Epub 2017 Oct 27.
OBJECTIVE Gamma Knife radiosurgery (GKRS) is frequently used to treat residual or recurrent nonfunctioning pituitary macroadenomas. There is no consensus as to whether GKRS should be used early after surgery or if radiosurgery should be withheld until there is evidence of imaging-defined progression of tumor. Given the high incidence of adenoma progression after subtotal resection over time, the present study intended to evaluate the effect of timing of radiosurgery on outcome. METHODS This is a multicenter retrospective review of patients with nonfunctioning pituitary macroadenomas who underwent transsphenoidal surgery followed by GKRS from 1987 to 2015 at 9 institutions affiliated with the International Gamma Knife Research Foundation. Patients were matched by adenoma and radiosurgical parameters and stratified based on the interval between last resection and radiosurgery. Operative results, imaging data, and clinical outcomes were compared across groups following early (≤ 6 months after resection) or late (> 6 months after resection) radiosurgery. RESULTS After matching, 222 patients met the authors' study criteria (from an initial collection of 496 patients) and were grouped based on early (n = 111) or late (n = 111) GKRS following transsphenoidal surgery. There was a greater risk of tumor progression after GKRS (p = 0.013) and residual tumor (p = 0.038) in the late radiosurgical group over a median imaging follow-up period of 68.5 months. No significant difference in the occurrence of post-GKRS endocrinopathy was observed (p = 0.68). Thirty percent of patients without endocrinopathy in the early cohort developed new endocrinopathies during the follow-up period versus 27% in the late cohort (p = 0.84). Fourteen percent of the patients in the early group and 25% of the patients in the late group experienced the resolution of endocrine dysfunction after original presentation (p = 0.32). CONCLUSIONS In this study, early GKRS was associated with a lower risk of radiological progression of subtotally resected nonfunctioning pituitary macroadenomas compared with expectant management followed by late radiosurgery. Delaying radiosurgery may increase patient risk for long-term adenoma progression. The timing of radiosurgery does not appear to significantly affect the rate of delayed endocrinopathy.
伽玛刀放射外科(GKRS)常用于治疗残留或复发性无功能垂体大腺瘤。对于术后早期是否应进行 GKRS 治疗,或者是否应在影像学定义的肿瘤进展证据出现后再进行放射外科治疗,尚无共识。鉴于次全切除术后腺瘤随时间进展的发生率较高,本研究旨在评估放射外科治疗时机对结局的影响。
这是一项多中心回顾性研究,纳入了 1987 年至 2015 年期间在国际伽玛刀研究基金会附属的 9 家机构接受经蝶窦手术和 GKRS 治疗的无功能垂体大腺瘤患者。通过腺瘤和放射外科参数对患者进行匹配,并根据末次切除与放射外科治疗之间的时间间隔进行分层。比较早期(切除后≤6 个月)或晚期(切除后>6 个月)放射外科治疗后各组的手术结果、影像学数据和临床结局。
匹配后,222 例患者符合作者的研究标准(最初纳入 496 例患者),并根据经蝶窦手术后早期(n=111)或晚期(n=111)GKRS 进行分组。在中位影像学随访 68.5 个月期间,晚期放射外科组中 GKRS 后肿瘤进展(p=0.013)和残留肿瘤(p=0.038)的风险更高。未观察到放射外科治疗后内分泌疾病发生率的显著差异(p=0.68)。在早期队列中无内分泌疾病的 30%患者在随访期间出现新的内分泌疾病,而晚期队列中为 27%(p=0.84)。在早期组中,14%的患者和晚期组中 25%的患者在原发表现后内分泌功能障碍得到缓解(p=0.32)。
在这项研究中,与期待治疗后再进行晚期放射外科治疗相比,早期 GKRS 与部分切除的无功能垂体大腺瘤的影像学进展风险较低相关。延迟放射外科治疗可能会增加患者长期腺瘤进展的风险。放射外科治疗的时机似乎不会显著影响迟发性内分泌疾病的发生率。